Malaria No More, the Crown Prince Court of Abu Dhabi, and the Reaching the Last Mile program launched the Institute for Malaria and Climate Solutions (IMACS) to combat malaria amidst climate change. Mohamed Bin Zayed University for Artificial Intelligence (MBZUAI) joined as a technical partner, providing research support leveraging AI and data science. The initiative aims to develop and implement AI-driven strategies to address the impact of climate change on malaria transmission. Why it matters: This partnership highlights the UAE's commitment to using AI for global health challenges, particularly in combating climate-sensitive diseases like malaria.
Malaria No More (MNM), Reaching the Last Mile (RLM), and MBZUAI have signed an agreement to expand the Forecasting Healthy Futures (FHF) initiative with a $5 million award from RLM. The initiative aims to address the impact of climate change on malaria and other climate-sensitive infectious diseases. MBZUAI will provide expertise to support the eradication of malaria. Why it matters: This partnership highlights the UAE's commitment to global health and leverages AI to combat climate-sensitive diseases, demonstrating a proactive approach to addressing complex global challenges.
MBZUAI is developing AI-powered applications to help reduce malaria's impact in Indonesia, supported by Sheikh Mohamed bin Zayed Al Nahyan's Reaching the Last Mile initiative. The applications use sensory data fusion to create "digital twins" for precise weather forecasting and real-time environmental representation. AI and clustering analysis identify recurring features contributing to malaria outbreaks, enabling preventative measures and early treatment. Why it matters: This project demonstrates AI's potential in combating climate-sensitive diseases and improving public health in vulnerable regions.
KAUST alumnus Abhinay Ramaprasad (M.S. '12, Ph.D. '17) has been awarded the Marie Skłodowska-Curie Fellowship from the European Commission. He will research malaria at the Francis Crick Institute in the U.K., focusing on the mechanisms of malaria parasite egress from red blood cells. Ramaprasad credits his time at KAUST and his work in Professor Arnab Pain's laboratory for preparing him for this opportunity. Why it matters: This fellowship recognizes the high-quality research training at KAUST and supports important work in combating a disease prevalent in many regions, reflecting KAUST's impact on global health.
Professor Arnab Pain's group at KAUST discovered new insights on how a malaria protein enables parasites to spread malaria in human cells. Professor Haavard Rue's group upgraded the Integrated and Nested Laplace Approximation (INLA) for faster real-time modeling of large datasets. A KAUST-led study examined the stability of Y-series nonfullerene acceptors for organic solar cells. Why it matters: KAUST continues producing impactful research across diverse fields from medicine to climate change, advancing scientific knowledge and potential applications.
KAUST researchers are developing a streamlined COVID-19 diagnostic testing method using superparamagnetic nanoparticles (MNPs). The team, led by Assistant Professor Mo Li, aims to address reagent shortages and improve automation by creating an in-house extraction kit compatible with inactivated samples. Associate Professor Samir Hamdan identified a protocol for making silica-coated MNPs that survive inactivation reagents, enabling magnetic separation without centrifugation. Why it matters: This innovation could significantly increase testing capacity in Saudi Arabia and globally by reducing biosafety risks, reagent dependence, and manual processing.
KAUST researchers are developing iSCAN, a rapid, field-deployable COVID-19 test using RT-LAMP coupled with CRISPR-Cas12. The iSCAN system is designed for rapid, specific detection of SARS-CoV-2 and can be deployed by untrained personnel. The researchers are benchmarking iSCAN against commercial kits and seeking emergency use authorization from the Saudi FDA. Why it matters: A rapid, accurate, and field-deployable COVID-19 test could significantly improve pandemic management and control in Saudi Arabia and beyond.
KAUST and Janssen Pharmaceutical (Johnson & Johnson) are collaborating to research and innovate in neglected tropical diseases, focusing on dengue fever. They signed an MoU to establish a dengue fever research program and an infectious disease R&D center at KAUST's National BioPark. The partnership marks Johnson & Johnson's first university collaboration in Saudi Arabia. Why it matters: This collaboration signifies a major step in localizing disease research within Saudi Arabia and leveraging KAUST's AI, genomics, and data simulation expertise to address global health challenges.